Company Overview and News

2
Sugar stocks ‘sweeten’ on govt bailout package

2018-06-06 thehindubusinessline
Shares of sugar producers climbed in the afternoon trade as the Union Cabinet has approved a Rs 8,500-crore bailout package for the sugar industry which includes Rs 4,500-crore soft loan for building ethanol production capacity and creating a 3-million-tonne stockpile to soak up excess supply.
BAJAJHIND 530363 UGARSUGAR NDAQ IDFCBANK DCMSHRIRAM 500032 523367 539437

0
Sugar stocks ‘sweeten’ on reports of bailout package

2018-06-05 thehindubusinessline
Sugar stocks rose up to 7 per cent today amid reports that the government is likely to announce a bailout package of over Rs 7,000 crore to ensure cash-starved mills clear dues to farmers at the earliest.
BAJAJHIND MAWANASUG BALRAMCHIN 523371 UTTAMSUGAR 532729 500119 500038 500032 DHAMPURSUG

0
Fire at Bajaj Hindusthan's Kinauni sugar mill

2018-05-28 thehindubusinessline
In another incident of fire, sugar major Bajaj Hindusthan Sugar has said that in the afternoon of Saturday, May 26, a fire broke out in one of the storage tanks of the company’s distillery division at Kinauni, Meerut, Uttar Pradesh, during loading of ethanol in containers.
BAJAJHIND 500032

0
Bajaj Hindusthan Sugar Limited - Updates

2018-05-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BAJAJHIND 500032

0
Bajaj Hindusthan Sugar posts Q4 loss at Rs158 crore

2018-05-27 livemint
New Delhi: Bajaj Hindusthan Sugar on Saturday reported a net loss of Rs157.77 crore in the March quarter of 2017-18. In the January-March period of the preceding financial year, its had a net profit of Rs 259.13 crore.
BAJAJHIND 500032

0
Bajaj Hindusthan Sugar Limited - Board Meeting Postponed

2018-05-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BAJAJHIND 500032

3
High-debt cos’ scrips suffer in Q1 of 2018

2018-04-13 thehindubusinessline
The first quarter of calendar year 2018 has not been too good for Indian investors, with benchmark indices reversing sharply in February.
BAJAJHIND BALRAMCHIN 534690 BHUSANSTL HIN 532712 514034 PNJZY RCOM 532461 LAKSHVILAS JBFIND PNB 500038 500185 500032 500055 HCC

10
Sugar stocks ‘sweeten’ as govt plans to pay Rs 55/t to cane farmers

2018-04-10 thehindubusinessline
The government plans to pay Rs 55 a tonne to cane farmers, while mills would pay the rest of the state-set price.
AXBKY BAJAJHIND BALRAMCHIN AXBA AXB AXISBANK 500119 500038 500032 532215 DHAMPURSUG

0
Bajaj Hindusthan Sugar Limited - Change in Director(s)

2018-03-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BAJAJHIND 500032

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...